Get the Stockscreener App
63.10
0.24%
0.15
Pre-market:
62.66
-0.44
-0.70%
Apogee Therapeutics Inc stock is traded at $63.10, with a volume of 716.71K.
It is up +0.24% in the last 24 hours and up +20.26% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$62.95
Open:
$63
24h Volume:
716.71K
Relative Volume:
1.06
Market Cap:
$2.91B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-22.91
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
+13.80%
1M Performance:
+20.26%
6M Performance:
+59.42%
1Y Performance:
+10.03%
1-Day Range:
$61.41
$64.87
1-Week Range:
$52.34
$64.87
52-Week Range:
$26.20
$64.87
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
63.10 | 3.88B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.19 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.72 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.74 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
889.89 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
377.47 | 36.43B | 4.56B | -176.77M | 225.30M | -1.7177 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Is Apogee Therapeutics Inc. stock positioned for digital transformationSwing Trade & Fast Momentum Stock Entry Tips - newser.com
How to use Fibonacci retracement on Apogee Therapeutics Inc.Portfolio Risk Report & Free Expert Verified Stock Movement Alerts - newser.com
Published on: 2025-11-12 14:24:11 - newser.com
Apogee Therapeutics stock hits 52-week high at 61.19 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics Reports Q3 2025 Financial Progress - TipRanks
Apogee Therapeutics’ Stock Surge: Is It Time To Jump In? - timothysykes.com
Apogee Therapeutics stock hits 52-week high at 61.19 USD - Investing.com India
Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Is Apogee Therapeutics Inc. stock recession proof2025 Major Catalysts & Free Growth Oriented Trading Recommendations - newser.com
Decoding Apogee Therapeutics Inc (APGE): A Strategic SWOT Insigh - GuruFocus
Understanding the Setup: (APGE) and Scalable Risk - news.stocktradersdaily.com
Key facts: Apogee's APG777 trial shows promise; $186.5M net loss reported - TradingView
Apogee Therapeutics Reports Positive Interim Results for APG333 Antibody - MarketScreener
Published on: 2025-11-10 09:17:09 - newser.com
Apogee Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Apogee Therapeutics Q3 Net Loss Widens - MarketScreener
Apogee Therapeutics, Inc. SEC 10-Q Report - TradingView
Apogee Therapeutics Provides Pipeline Progress - TradingView
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results - The Manila Times
Apogee Therapeutics Updates Pipeline Progress and Financial Results, Anticipates Four Key Clinical Data Readouts in 2026 - Quiver Quantitative
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody - The Manila Times
Apogee Therapeutics (NASDAQ: APGE) Phase 1 shows 6-month biomarker suppression, APG333 - Stock Titan
Apogee Therapeutics to Participate in Upcoming Conferences - Sahm
Will Apogee Therapeutics Inc. stock split attract more investorsTrend Reversal & Safe Capital Allocation Plans - newser.com
Apogee Therapeutics Inc Stock Analysis and ForecastEarnings Growth Projections & Free Unlock Exclusive Strategies - earlytimes.in
Apogee Therapeutics CMO sells $593,902 in shares By Investing.com - Investing.com Canada
[Form 4] Apogee Therapeutics, Inc. Insider Trading Activity - Stock Titan
Published on: 2025-11-07 02:10:36 - newser.com
How to track smart money flows in Apogee Therapeutics Inc.2025 Market WrapUp & Accurate Trade Setup Notifications - newser.com
CEO Moves: Is Apogee Therapeutics Inc. stock cheap at current valuation2025 Pullback Review & Safe Entry Momentum Stock Tips - Fundação Cultural do Pará
Will breakout in Apogee Therapeutics Inc. lead to full recoveryRate Hike & Weekly Setup with ROI Potential - newser.com
How to read the order book for Apogee Therapeutics Inc.Weekly Trend Report & Technical Entry and Exit Tips - newser.com
Is Apogee Therapeutics Inc. stock a dividend growth opportunity2025 AllTime Highs & Consistent Return Strategy Ideas - newser.com
How to integrate Apogee Therapeutics Inc. into portfolio analysis toolsJuly 2025 Review & Weekly Breakout Watchlists - newser.com
Detecting support and resistance levels for Apogee Therapeutics Inc.Risk Management & Daily Profit Focused Screening - newser.com
Apogee Therapeutics (APGE) to Release Earnings on Tuesday - MarketBeat
Craig-Hallum bullish on Apogee Therapeutics, initiates with a Buy - MSN
Real time scanner hits for Apogee Therapeutics Inc. explainedQuarterly Trade Report & Risk Controlled Stock Pick Alerts - newser.com
Apogee Therapeutics (NASDAQ:APGE) Given New $70.00 Price Target at Royal Bank Of Canada - MarketBeat
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):